AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ganirelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| gonadotropin-releasing-hormone (GnRH) inhibitors, peptides | 1279 | 124904-93-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As result a rapid, profound,reversible suppression of endogenous gonadotropins occurs, without initial stimulation as induced by GnRH agonists.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.21 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.63 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.18 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.09 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 1999 | FDA | ORGANON USA INC | |
| May 16, 2000 | EMA | N.V. ORGANON |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 5008.30 | 62.35 | 695 | 2593 | 5167 | 90619992 |
| Ascites | 849.99 | 62.35 | 219 | 3069 | 47521 | 90577638 |
| Ovarian haemorrhage | 291.90 | 62.35 | 42 | 3246 | 369 | 90624790 |
| Ovarian enlargement | 187.01 | 62.35 | 30 | 3258 | 570 | 90624589 |
| Haemoperitoneum | 156.10 | 62.35 | 34 | 3254 | 3494 | 90621665 |
| Inappropriate schedule of product administration | 144.08 | 62.35 | 81 | 3207 | 149852 | 90475307 |
| Pleural effusion | 139.75 | 62.35 | 72 | 3216 | 111919 | 90513240 |
| Abdominal distension | 132.09 | 62.35 | 73 | 3215 | 130528 | 90494631 |
| Pelvic fluid collection | 130.62 | 62.35 | 24 | 3264 | 1035 | 90624124 |
| Maternal exposure before pregnancy | 121.51 | 62.35 | 35 | 3253 | 11178 | 90613981 |
| Intra-abdominal haemorrhage | 92.18 | 62.35 | 21 | 3267 | 2641 | 90622518 |
| Adnexal torsion | 84.83 | 62.35 | 15 | 3273 | 519 | 90624640 |
| Abdominal pain lower | 77.25 | 62.35 | 32 | 3256 | 30145 | 90595014 |
| Needle issue | 73.12 | 62.35 | 25 | 3263 | 13909 | 90611250 |
| Haemoconcentration | 64.41 | 62.35 | 10 | 3278 | 152 | 90625007 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 4790.14 | 68.92 | 626 | 1952 | 4734 | 110581987 |
| Ascites | 770.94 | 68.92 | 212 | 2366 | 92596 | 110494125 |
| Ovarian haemorrhage | 307.59 | 68.92 | 41 | 2537 | 319 | 110586402 |
| Ovarian enlargement | 211.59 | 68.92 | 30 | 2548 | 382 | 110586339 |
| Pelvic fluid collection | 141.84 | 68.92 | 24 | 2554 | 1009 | 110585712 |
| Haemoperitoneum | 134.57 | 68.92 | 30 | 2548 | 5358 | 110581363 |
| Pleural effusion | 132.89 | 68.92 | 70 | 2508 | 177639 | 110409082 |
| Maternal exposure before pregnancy | 105.18 | 68.92 | 26 | 2552 | 7239 | 110579482 |
| Adnexal torsion | 94.51 | 68.92 | 15 | 2563 | 421 | 110586300 |
| Abdominal distension | 87.43 | 68.92 | 53 | 2525 | 175050 | 110411671 |
| Abdominal pain lower | 84.45 | 68.92 | 32 | 2546 | 37251 | 110549470 |
| Intra-abdominal haemorrhage | 81.78 | 68.92 | 20 | 2558 | 5322 | 110581399 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H01CC01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones |
| FDA PE | N0000008638 | Decreased GnRH Secretion |
| FDA MoA | N0000175084 | Gonadotropin Releasing Hormone Receptor Antagonists |
| MeSH PA | D006727 | Hormone Antagonists |
| FDA EPC | N0000175839 | Gonadotropin Releasing Hormone Receptor Antagonist |
Related Drugs by ATC class:
H01CC Anti-gonadotropin-releasing hormones 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ovulation induction | indication | 61285001 | |
| Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation | indication | ||
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.09 | acidic |
| pKa3 | 12.73 | acidic |
| pKa4 | 13.33 | acidic |
| pKa5 | 13.33 | acidic |
| pKa6 | 13.78 | acidic |
| pKa7 | 8.8 | Basic |
| pKa8 | 8.2 | Basic |
| pKa9 | 5.35 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing hormone receptor | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021229 | VUID |
| N0000148673 | NUI |
| D04302 | KEGG_DRUG |
| 4021229 | VANDF |
| 4021230 | VANDF |
| C0073629 | UMLSCUI |
| CHEMBL1251 | ChEMBL_ID |
| CHEMBL5314377 | ChEMBL_ID |
| DB06785 | DRUGBANK_ID |
| C061018 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3877 | IUPHAR_LIGAND_ID |
| 6830 | INN_ID |
| 129311-55-3 | SECONDARY_CAS_RN |
| IX503L9WN0 | UNII |
| 16130957 | PUBCHEM_CID |
| 259264 | RXNORM |
| 399987 | MMSL |
| 67714 | MMSL |
| 8280 | MMSL |
| d04447 | MMSL |
| 008055 | NDDF |
| 008056 | NDDF |
| 116102008 | SNOMEDCT_US |
| 326088005 | SNOMEDCT_US |
| 395728002 | SNOMEDCT_US |
| CHEBI:135910 | CHEBI |
| IX503L9WN0 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-5001 | INJECTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| Fyremadel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-1010 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-028 | INJECTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67184-0574 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| GANIRELIX ACETATE | Human Prescription Drug Label | 1 | 68083-472 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 11 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-327 | INJECTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70748-274 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 19 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-554 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-138 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | NDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-138 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | NDA | 23 sections |
| Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83301-0082 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 22 sections |